Peter D van der Ark (Peter van der Ark)

Publication Activity (10 Years)

Years Active: 2018-2019
Publications (10 Years): 3

Top Topics

Major Depressive Disorder

Placebo Controlled

Top Venues

Journal of psychopharmacology (Oxford, England)

Janssen Pharmaceutica NV

Universiteit Leiden (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Janssen Pharmaceutica NV Jun 01 2005

Belgium

Clinical Scientist :: Experimental Medicine Neuroscience

Education History

Universiteit Leiden Aug 01 1976 - Nov 01 1983

Netherlands

MSC :: Biology

Publications

Sander Brooks, Gabriël E Jacobs, Peter De Boer, Justine M Kent, Luc Van Nueten, Guido van Amerongen, Rob Zuiker, Iva Kezic, Remy Luthringer, Peter D van der Ark, Joop Ma van Gerven, Wayne Drevets
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. Journal of psychopharmacology (Oxford, England) 33 (2) (2019)
Peter De Boer, Wayne C Drevets, Hany Rofael, Peter D van der Ark, Justine M Kent, Iva Kezic, Silvia Parapatics, Georg Dorffner, Joop van Gerven, Heike Beneš, Christian Keicher, Holger Jahn, David J Seiden, Remy Luthringer
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. Journal of psychopharmacology (Oxford, England) 32 (6) (2018)
Peter D van der Ark, Georg Golor, Luc van Nueten, Partha Nandy, Peter De Boer
Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects. Journal of psychopharmacology (Oxford, England) 32 (12) (2018)